Article Text

Insulin-like growth factor binding protein 1 protects against endothelial dysfunction
  1. A Rajwani1,
  2. J Surr1,
  3. KE Porter1,
  4. H Viswambharan1,
  5. H Imrie1,
  6. A Abbas1,
  7. R Cubbon1,
  8. V Ezzat2,
  9. MT Kearney1,
  10. SB Wheatcroft1
  1. 1University of Leeds, Leeds, UK
  2. 2Kings College London, London, UK


Background Insulin-like growth factor binding proteins (IGFBP) are key regulators of insulin-like growth factor (IGF) type 1 bioavailability at the cellular level and may also exert IGF-independent effects on target cells. In cross-sectional studies, circulating levels of IGFBP-1 inversely correlate with insulin resistance and vascular disease. In a previous study of transgenic mice overexpressing IGFBP-1 (but with intact fast/feed regulation of this axis), we showed a favourable effect on endothelial function and blood pressure, mediated by increased vascular nitric oxide. We thus sought to explore the hypothesis that IGFBP-1 favourably modulates metabolic homeostasis and vascular endothelial function in the setting of dietary obesity.

Methods Male C57Bl/6 mice with transgenic IGFBP-1 overexpression and littermate controls were fed an obesogenic diet, with subsequent metabolic and non-invasive haemodynamic testing in conscious mice. Endothelial function was assessed ex vivo in the organ bath by testing insulin-mediated blunting of vasoconstriction in excised aorta. These studies were complemented by Western blot assay of aortic endothelial nitric oxide synthase (eNOS) phosphorylation after in-vivo intraperitoneal insulin bolus (0.75 IU/kg). Separate in-vitro studies in the organ bath examined the vasomotor effect of exogenous IGFBP-1 (500 ng/ml) in healthy murine aorta. Western blot was used to study the effects of IGFBP-1 (500 ng/ml) on signalling pathways in cultured human coronary artery endothelial cells.

Abstract 065 Figure 1

IGFBP-1, insulin-like growth factor binding protein 1.

Abstract 065 Figure 2

IGFBP-1, insulin-like growth factor binding protein 1; peNOS, preserved endothelial nitric oxide synthase.

Abstract 065 Table

Results Weight-gain in response to a high-fat diet was unaltered by IGFBP-1 overexpression. However, transgenic obese mice were significantly more insulin-sensitive, glucose-tolerant, and less hypertensive (table). Insulin-mediated inhibition of vasoconstriction in the organ bath is lost in obese wild-type aorta, but relatively preserved in transgenic aorta. Preliminary study of signalling pathways in aorta after insulin challenge suggest preserved eNOS phosphorylation in obese transgenic compared with obese wild-type mice. Exogenous IGFBP-1 abrogates vasoconstriction in healthy lean aorta (fig 1; maximal constriction 0.46 ± 0.05 g with IGFBP-1, 0.67 ± 0.05 g without IGFBP-1, p = 0.02, n  =  5), an effect that was completely abolished by the eNOS inhibitor l-NMMA. Moreover, ser1177eNOS phosphorylation in cultured endothelial cells was significantly increased by IGFBP-1 (fig 2; normalised ser1177eNOS level compared with control 202 ± 32%, p = 0.03, n  =  5).

Implications These data demonstrate novel actions of IGFBP-1, with rescue of endothelial function in a model of insulin-resistance through preserved insulin-sensitivity and increased nitric oxide production. Attenuated IGFBP-1 levels in insulin-resistant states are thus implicated in endothelial dysfunction and pro-atherogenesis.

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.